Several therapeutic agents (as the anti-BAFF antibody Lymphostat-B, the BAFF-antagonist AMG-623, and decoy fusion proteins TACI-Fc/Atacicept, BCMA-Fc, BR3-Fc) are being assessed for the targeted disruption of the BAFF-system in B-cell disorders and hematological malignancies.[8], [31] Studies are necessary to define the critical role of BAFF-system-triggered signals in B-ALL development, and to validate BAFF-system targeting as a valid strategy for the treatment of B-ALL patients. This evidence concerns the gene TNFRSF13C and precursor B-cell acute lymphoblastic leukemia.